
Loading, please wait...

Loading, please wait...

The phase 3b TEMPLE trial directly compared atogepant 60 mg once daily with the highest tolerated dose of topiramate (50–100 mg/day) for migraine prevention. Among 545 randomized participants, treatment discontinuation because of treatment-emergent adverse events was significantly lower with atogepant than topiramate (12.1% vs 29.6%; RR 0.41, 95% CI 0.28–0.59; P<0.0001). Overall adverse events occurred in 76.9% and 88.8% of participants, respectively, while treatment-related adverse events occurred in 56.0% versus 77.9%. Atogepant also demonstrated greater efficacy: 64.1% achieved at least a 50% reduction in mean monthly migraine days compared with 39.3% with topiramate (RR 1.63, 95% CI 1.37–1.95; P<0.0001). Mean monthly migraine days decreased by 6.27 days with atogepant versus 4.49 days with topiramate, representing a between-group difference of −1.78 days (95% CI −2.52 to −1.04; P<0.0001). No new safety signals were identified.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The phase 3b TEMPLE trial directly compared atogepant 60 mg once daily with the highest tolerated dose of topiramate (50–100 mg/day) for migraine prevention. Among 545 randomized participants, treatment discontinuation because of treatment-emergent adverse events was significantly lower with atogepant than topiramate (12.1% vs 29.6%; RR 0.41, 95% CI 0.28–0.59; P<0.0001). Overall adverse events occurred in 76.9% and 88.8% of participants, respectively, while treatment-related adverse events occurred in 56.0% versus 77.9%. Atogepant also demonstrated greater efficacy: 64.1% achieved at least a 50% reduction in mean monthly migraine days compared with 39.3% with topiramate (RR 1.63, 95% CI 1.37–1.95; P<0.0001). Mean monthly migraine days decreased by 6.27 days with atogepant versus 4.49 days with topiramate, representing a between-group difference of −1.78 days (95% CI −2.52 to −1.04; P<0.0001). No new safety signals were identified.
2 months ago

Researchers have identified compound 8g, an orally bioavailable corydamine derivative that targets glutathione reductase. By dismantling redox defenses and disrupting NADPH homeostasis, 8g acts synergistically with sorafenib to trigger apoptosis and overcome drug resistance in hepatocellular carcinoma models.
Yesterday

A breakthrough blood test measuring the RNA biomarker Tu-Stroma detects microscopic serous tubal intraepithelial carcinoma (STIC) lesions with remarkable accuracy. This non-invasive diagnostic tool offers crucial biological insight to guide prophylactic surgery decisions for women carrying high-risk genetic mutations.
2 days back

Researchers have engineered novel light-on photoswitchable adrenoceptor agonists targeting β1-receptors. By remaining inactive until illuminated, these precision molecules offer reversible optical control, tailored relaxation kinetics, and distinct efficacy profiles, paving the way for targeted cardiovascular therapies.
Yesterday

A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 weeks back

A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 weeks back